Compare MLKN & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLKN | TBPH |
|---|---|---|
| Founded | 1905 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 993.7M |
| IPO Year | N/A | N/A |
| Metric | MLKN | TBPH |
|---|---|---|
| Price | $18.27 | $18.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $27.80 |
| AVG Volume (30 Days) | ★ 815.2K | 475.1K |
| Earning Date | 12-17-2025 | 11-10-2025 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | ★ $3,748,900,000.00 | $80,327,000.00 |
| Revenue This Year | $6.57 | $70.78 |
| Revenue Next Year | $4.45 | N/A |
| P/E Ratio | ★ N/A | $32.24 |
| Revenue Growth | 4.34 | ★ 27.12 |
| 52 Week Low | $13.77 | $7.90 |
| 52 Week High | $23.47 | $20.33 |
| Indicator | MLKN | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 67.51 | 57.48 |
| Support Level | $17.87 | $18.51 |
| Resistance Level | $18.49 | $18.97 |
| Average True Range (ATR) | 0.57 | 0.58 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 69.93 | 78.37 |
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).